Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia

Trial Profile

International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Daunorubicin liposomal; Fludarabine; Fludarabine; Methotrexate; Prednisolone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms Pediatric Relapsed AML 2010/01
  • Most Recent Events

    • 15 Sep 2022 This trial has been completed in Germany (Global End Date: 8 Jan 2020), according to European Clinical Trials Database record.
    • 12 Feb 2020 This trial has been discontinued in Germany, according to European Clinical Trials Database.
    • 17 Jan 2020 This trial has been discontinued in Czech Republic , according to European Clinical Trials Database.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top